TuHURA Biosciences (HURA) and Kineta (KANT) Receive Stockholders Approval of Proposed Merger and All Related Proposals

TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc. (OTC Pink: KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, that TuHURA stockholders approved all of the proposals set forth at the Company's Special Meeting of Stockholders held today, June 23, 2025 (the "TuHURA Special Meeting"). The proposals included an increase of the Company's authorized shares to 200 million shares and a proposal to reincorporate the Company in Delaware.

Additionally, Kineta stockholders approved the proposed merger (the "Merger") with TuHURA at Kineta's Special Meeting of Stockholders held today, June 23, 2025 (the "Kineta Special Meeting"). The parties anticipate that the Merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.

The final voting results of the TuHURA Special Meeting and the Kineta Special Meeting will be reported in Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

You May Also Be Interested In

• Civista Bancshares agrees to acquire Farmers Savings Bank for $70.4 million
• Toll Brothers names Gregg Ziegler as new CFO replacing Marty Connor
• FDA approves Merck's BRAVECTO QUANTUM for year-long flea and tick protection